Tedizolid HCl is a reversible, novel oxazolidinone antibiotic (IC50: for MAO-A (monoamine oxidase-A), 8.7 uM; for MAO-B, 5.7 uM). It is the first oxazolidinone to be approved since linezolid in 2000. Tedizolid phosphate is the second commercially available oxazolidinone antibiotic and is the prodrug form of tedizolid with a fixed once-daily dose. As an expanded-spectrum oxazolidinone, it has potent activity against a wide range of Gram-positive pathogens.